CL2020003070A1 - Selección y uso de bacterias de apoyo de melatonina para reducir el cólico infantil - Google Patents
Selección y uso de bacterias de apoyo de melatonina para reducir el cólico infantilInfo
- Publication number
- CL2020003070A1 CL2020003070A1 CL2020003070A CL2020003070A CL2020003070A1 CL 2020003070 A1 CL2020003070 A1 CL 2020003070A1 CL 2020003070 A CL2020003070 A CL 2020003070A CL 2020003070 A CL2020003070 A CL 2020003070A CL 2020003070 A1 CL2020003070 A1 CL 2020003070A1
- Authority
- CL
- Chile
- Prior art keywords
- melatonin
- selection
- strains
- production
- infant colic
- Prior art date
Links
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title abstract 4
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title abstract 4
- 229960003987 melatonin Drugs 0.000 title abstract 4
- 206010021746 Infantile colic Diseases 0.000 title abstract 2
- 241000894006 Bacteria Species 0.000 title 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 208000002881 Colic Diseases 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/38—Nucleosides
- C12P19/40—Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03031—Nucleotidase (3.1.3.31)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a cepas bacterianas de ácido láctico que son capaces de producir o inducir la producción de melatonina, para su uso en la producción de melatonina en un sujeto. Las cepas preferidas para tales usos son capaces de producir o inducir la producción de adenosina. Los usos terapéuticos de tales cepas incluyen el tratamiento o la prevención de <br /> enfermedades asociadas con la deficiencia de melatonina, por ejemplo, el cólico infantil. También se proporcionan nuevas cepas
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1812079.0A GB201812079D0 (en) | 2018-07-24 | 2018-07-24 | Selection method |
| GBGB1905470.9A GB201905470D0 (en) | 2019-04-17 | 2019-04-17 | Selection method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020003070A1 true CL2020003070A1 (es) | 2021-04-05 |
Family
ID=67390083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020003070A CL2020003070A1 (es) | 2018-07-24 | 2020-11-26 | Selección y uso de bacterias de apoyo de melatonina para reducir el cólico infantil |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11911424B2 (es) |
| EP (2) | EP4086359A1 (es) |
| JP (2) | JP7488199B2 (es) |
| KR (1) | KR20210035077A (es) |
| CN (2) | CN112236513B (es) |
| AU (1) | AU2019309426A1 (es) |
| BR (1) | BR112020023868A2 (es) |
| CA (1) | CA3099255A1 (es) |
| CL (1) | CL2020003070A1 (es) |
| CO (1) | CO2020014673A2 (es) |
| DK (1) | DK3701051T3 (es) |
| ES (1) | ES2928223T3 (es) |
| GE (1) | GEP20237507B (es) |
| HR (1) | HRP20221209T1 (es) |
| HU (1) | HUE059963T2 (es) |
| IL (1) | IL305597B1 (es) |
| LT (1) | LT3701051T (es) |
| MX (1) | MX2020012770A (es) |
| PH (1) | PH12020551922A1 (es) |
| PL (1) | PL3701051T3 (es) |
| PT (1) | PT3701051T (es) |
| RS (1) | RS63624B1 (es) |
| SG (1) | SG11202010900PA (es) |
| WO (1) | WO2020020982A1 (es) |
| ZA (1) | ZA202006891B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3827102A1 (en) * | 2018-07-24 | 2021-06-02 | Biogaia AB | Therapeutic methods using bacterial strains which are capable of increasing adenosine levels |
| CN115040551B (zh) * | 2022-06-08 | 2023-07-25 | 华南农业大学 | 一株调控宿主褪黑素水平的罗伊氏乳酸杆菌ln0214的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7374924B2 (en) | 2006-06-05 | 2008-05-20 | Biogaia Ab | Use of selected lactic acid bacteria for reducing infantile colic |
| WO2008016911A2 (en) | 2006-07-31 | 2008-02-07 | Oregon Health & Science University | Replicating melatonin signaling in a fetus, newborn or suckling infant |
| KR100913406B1 (ko) | 2008-03-25 | 2009-08-21 | 광주과학기술원 | Ｔｈ１－매개 면역 질환의 예방 또는 치료용 조성물 |
| KR100913405B1 (ko) | 2008-03-25 | 2009-08-21 | 광주과학기술원 | Ｔｈ２－매개 면역 질환의 예방 또는 치료용 조성물 |
| EP2352393A1 (en) | 2008-11-03 | 2011-08-10 | Nestec S.A. | A nutritional composition comprising probiotics and improving sleep patterns |
| EP2452575A1 (en) | 2010-11-15 | 2012-05-16 | Nestec S.A. | Array of age-tailored nutritional formula with probiotics |
| EP2609813A1 (en) | 2011-12-30 | 2013-07-03 | Nestec S.A. | Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system |
| ITMI20120471A1 (it) | 2012-03-26 | 2013-09-27 | Giovanni Mogna | Composizione a base di ceppi di batteri bifidobacterium longum in grado di aiutare il prolungamento della vita |
| GB201206599D0 (en) | 2012-04-13 | 2012-05-30 | Univ Manchester | Probiotic bacteria |
| EP2674162A1 (en) | 2012-05-29 | 2013-12-18 | Danuta Kruszewska | Nanoproduct comprising lactobacillus reuteri dan080 useful in prophylaxis and medicine, both human and veterinary and medical use of the same |
| UA118339C2 (uk) | 2012-09-03 | 2019-01-10 | Біогайа Аб | Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти) |
| WO2015112083A1 (en) | 2014-01-23 | 2015-07-30 | Biogaia Ab | Selection of agents modulating gastrointestinal pain |
| WO2015177246A2 (en) * | 2014-05-20 | 2015-11-26 | Biogaia Ab | Neonatal microbiome supplementation |
| CN106460029A (zh) | 2014-06-30 | 2017-02-22 | 株式会社明治 | 抑制嘌呤吸收的乳酸菌及其用途 |
| WO2016102660A1 (en) | 2014-12-23 | 2016-06-30 | PHILLIPSON, Mia | Methods for wound healing |
| MX2017012359A (es) | 2015-03-26 | 2018-07-06 | Biogaia Ab | Cepas bacterianas productoras de histamina y su uso en cancer. |
| CN110087656A (zh) | 2016-05-27 | 2019-08-02 | 拜奥加亚公司 | 肌苷在治疗T-reg缺乏中的应用 |
| WO2017223364A1 (en) | 2016-06-23 | 2017-12-28 | Erdman Susan E | Canine microbe preparations for increasing oxytocin |
| CN108029923A (zh) | 2017-12-13 | 2018-05-15 | 杭州滨研生物科技有限公司 | 一种具有抗过敏效果的益生菌固体饮料生产配方 |
| EP3827102A1 (en) * | 2018-07-24 | 2021-06-02 | Biogaia AB | Therapeutic methods using bacterial strains which are capable of increasing adenosine levels |
-
2019
- 2019-07-24 IL IL305597A patent/IL305597B1/en unknown
- 2019-07-24 CN CN201980036257.3A patent/CN112236513B/zh active Active
- 2019-07-24 JP JP2020570056A patent/JP7488199B2/ja active Active
- 2019-07-24 CA CA3099255A patent/CA3099255A1/en active Pending
- 2019-07-24 US US16/961,598 patent/US11911424B2/en active Active
- 2019-07-24 EP EP22165915.4A patent/EP4086359A1/en active Pending
- 2019-07-24 EP EP19742381.7A patent/EP3701051B1/en active Active
- 2019-07-24 AU AU2019309426A patent/AU2019309426A1/en active Pending
- 2019-07-24 SG SG11202010900PA patent/SG11202010900PA/en unknown
- 2019-07-24 RS RS20220933A patent/RS63624B1/sr unknown
- 2019-07-24 PL PL19742381.7T patent/PL3701051T3/pl unknown
- 2019-07-24 ES ES19742381T patent/ES2928223T3/es active Active
- 2019-07-24 BR BR112020023868-6A patent/BR112020023868A2/pt unknown
- 2019-07-24 HR HRP20221209TT patent/HRP20221209T1/hr unknown
- 2019-07-24 PT PT197423817T patent/PT3701051T/pt unknown
- 2019-07-24 HU HUE19742381A patent/HUE059963T2/hu unknown
- 2019-07-24 WO PCT/EP2019/069984 patent/WO2020020982A1/en unknown
- 2019-07-24 KR KR1020207033397A patent/KR20210035077A/ko unknown
- 2019-07-24 MX MX2020012770A patent/MX2020012770A/es unknown
- 2019-07-24 CN CN202311089611.3A patent/CN117487686A/zh active Pending
- 2019-07-24 DK DK19742381.7T patent/DK3701051T3/da active
- 2019-07-24 LT LTEPPCT/EP2019/069984T patent/LT3701051T/lt unknown
- 2019-07-24 GE GEAP201915500A patent/GEP20237507B/en unknown
-
2020
- 2020-11-04 ZA ZA2020/06891A patent/ZA202006891B/en unknown
- 2020-11-11 PH PH12020551922A patent/PH12020551922A1/en unknown
- 2020-11-26 CL CL2020003070A patent/CL2020003070A1/es unknown
- 2020-11-26 CO CONC2020/0014673A patent/CO2020014673A2/es unknown
-
2024
- 2024-01-18 US US18/416,049 patent/US20240216447A1/en active Pending
- 2024-03-26 JP JP2024048924A patent/JP2024091643A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202010900PA (en) | 2020-12-30 |
| PH12020551922A1 (en) | 2021-06-14 |
| LT3701051T (lt) | 2022-12-12 |
| HUE059963T2 (hu) | 2023-01-28 |
| RS63624B1 (sr) | 2022-10-31 |
| PT3701051T (pt) | 2022-10-17 |
| CN112236513B (zh) | 2023-09-19 |
| PL3701051T3 (pl) | 2022-10-31 |
| AU2019309426A1 (en) | 2021-03-11 |
| US20240216447A1 (en) | 2024-07-04 |
| HRP20221209T1 (hr) | 2022-12-09 |
| GEP20237507B (en) | 2023-05-25 |
| DK3701051T3 (da) | 2022-10-03 |
| IL305597A (en) | 2023-11-01 |
| EP3701051A1 (en) | 2020-09-02 |
| WO2020020982A1 (en) | 2020-01-30 |
| IL305597B1 (en) | 2024-04-01 |
| CO2020014673A2 (es) | 2020-12-21 |
| EP3701051B1 (en) | 2022-07-13 |
| CN117487686A (zh) | 2024-02-02 |
| EP4086359A1 (en) | 2022-11-09 |
| MX2020012770A (es) | 2021-02-15 |
| ZA202006891B (en) | 2023-03-29 |
| BR112020023868A2 (pt) | 2021-04-06 |
| JP2024091643A (ja) | 2024-07-05 |
| JP2021531739A (ja) | 2021-11-25 |
| US11911424B2 (en) | 2024-02-27 |
| CA3099255A1 (en) | 2020-01-30 |
| US20220347237A1 (en) | 2022-11-03 |
| ES2928223T3 (es) | 2022-11-16 |
| CN112236513A (zh) | 2021-01-15 |
| JP7488199B2 (ja) | 2024-05-21 |
| KR20210035077A (ko) | 2021-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001178A1 (es) | Procesos para la producción de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia | |
| CO2019011995A2 (es) | Procesos para la producción de linfocitos infiltrantes de tumores y usos de ellos en inmunoterapia | |
| CO2020007142A2 (es) | Composiciones y métodos para el tratamiento de los trastornos inmunitarios utilizando cepas de bacterias inmunomoduladoras de lactococcus | |
| CO2020010956A2 (es) | Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| CY1119840T1 (el) | Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων | |
| CL2019002135A1 (es) | Células microbianas, métodos para producir las mismas, y usos de las mismas. | |
| CL2020003070A1 (es) | Selección y uso de bacterias de apoyo de melatonina para reducir el cólico infantil | |
| PA8815001A1 (es) | Piridinil amidas para el tratamiento de trastornos del snc y metabolicos | |
| GT201400222A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
| DOP2015000147A (es) | Derivados de imidazopiridazina como moduladores del receptor gabaa | |
| MX2018008645A (es) | Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| CO2017002312A2 (es) | Compuestos bicíclicos sustituidos | |
| BR112018004257A2 (pt) | composto e composição farmacêutica | |
| BR112015010225A2 (pt) | compostos tricíclicos e seus métodos de produção e utilização | |
| MX2021012631A (es) | Microvesiculas terapeuticas de bacterias probioticas. | |
| MX2018008640A (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano. | |
| NZ745185A (en) | 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| CO2023000114A2 (es) | Composiciones y métodos para el tratamiento de enfermedades y trastornos usando vesículas extracelulares microbianas de oscillospiraceae | |
| CL2019003084A1 (es) | Tratamiento de cólicos infantiles. | |
| MX2020014222A (es) | Metodos terapeuticos que utilizan cepas bacterianas las cuales son capaces de aumentar los niveles de adenosina. | |
| AR107460A1 (es) | Gabapentina oftálmica para el tratamiento de las úlceras corneales | |
| AR122609A1 (es) | Composiciones y métodos para el tratamiento de enfermedades y trastornos usando fournierella massiliensis | |
| AR122608A1 (es) | Composiciones y métodos para el tratamiento de enfermedades y trastornos usando harryflintia acetispora | |
| RU2009119225A (ru) | Способ лечения и профилактики кокцидиозов норок |